homemarket NewsBlue Jet Healthcare sets price band at ₹329 346 per share, looks to raise ₹840 cr through IPO

Blue Jet Healthcare sets price band at ₹329-346 per share, looks to raise ₹840 cr through IPO

Blue Jet Healthcare's public issue is expected to fetch ₹799 crore and ₹840.27 crore at the lower and upper ends of the price band, respectively. Investors can bid for a minimum of 43 equity shares and in multiples of 43 equity shares thereafter, as per PTI.

Profile image

By PTI Oct 19, 2023 5:37:00 PM IST (Published)

Listen to the Article(6 Minutes)
2 Min Read
Blue Jet Healthcare sets price band at ₹329-346 per share, looks to raise ₹840 cr through IPO
Pharmaceutical ingredient maker Blue Jet Healthcare on Thursday fixed a price band of 329-346 per share for its 840 crore Initial Public Offering (IPO). The bidding for the issue, which is entirely an Offer for Sale (OFS) component of 2.42 crore shares by promoters—Akshay Bansarilal Arora and Shiven Akshay Arora—will open for public subscription during October 25-27.

Share Market Live

View All

The anchor book for the issue will open on October 23, the company said. Since the IPO is completely an OFS, the entire proceeds will go to the selling shareholders, and the company will not receive any funds from the issue.
The maiden public issue is expected to fetch 799 crore and 840.27 crore at the lower and upper ends of the price band, respectively. Investors can bid for a minimum of 43 equity shares and in multiples of 43 equity shares thereafter.
The Mumbai-based firm, which operates under the "Blue Jet" brand name, is offering niche products targeted towards innovator pharmaceutical companies and multinational generic pharmaceutical companies. Its business model focuses on the collaboration, development and manufacturing of complex chemistry categories. Over the past five decades, the company has developed over 100 products, of which over 40 have been commercialised.
As of June 30, 2023, the company had three manufacturing facilities in Shahad, Ambernath, and Mahad in Maharashtra. Further, in its efforts to expand the capacity in FY21, it acquired a "greenfield" industrial facility on a leasehold basis in Ambernath. In FY22, 76% of the company's income came from Europe, followed by India (17.14%), the US (4.18%), and some other countries.
Kotak Mahindra Capital Company Ltd, ICICI Securities Ltd and JP Morgan India Pvt Ltd are the book running lead managers to the issue. The equity shares of Blue Jet Healthcare are proposed to be listed on the BSE and the NSE.

Most Read

Share Market Live

View All
Top GainersTop Losers
CurrencyCommodities
CurrencyPriceChange%Change